Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 4 Study of Adjunctive Perampanel (Fycompa) in Pediatric Childhood Epilepsy
2023-507794-17-00Phase 2Authorised
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of perampanel in epilepsy, epilepsy syndrome and Focal onset seizure, sponsored by Eisai Co., Ltd. Primary endpoint: Proportion of 50% responders for all seizures during the Maintenance Period of Core Study. Planned start May 2024; status: authorised.
02
Drugs
perampanel
03
Conditions
epilepsyepilepsy syndromeFocal onset seizure
Beyond the preview
Go deeper on 2023-507794-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507794-17-00.